dimanche 15 novembre 2026
RechercherExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
Source document· January 18, 2026

2 Top Flying Car Stocks That Cathie Wood Can’t Get Enough Of

View original at finance.yahoo.com
“Quarterly revenue jumped to $22.6 million from just $0.03 million in the year-ago quarter, thanks largely to the August acquisition of Blade's passenger business.”
Verbatim excerpt from the source · short snapshot: read the full document at the original

Ce que nous avons tiré de cette source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Joby plans to produce four aircraft a month by 2027 at Ohio facility

    80% confidence
  • Urban air mobility has long lived somewhere between science fiction and city planning decks

    80% confidence
  • For Archer fiscal 2026, losses expected to reduce 7.8% annually to -$0.95 per share

    80% confidence
  • For Joby, current quarter loss per share expected to widen 5.3% YOY to -$0.20

    80% confidence
  • For Archer current quarter, losses expected to decrease 52.8% YOY to -$0.25 per share

    80% confidence
  • Management expects to generate cash, cash equivalents, and short-term investments at the upper end of $500 million to $540 million range for 2025

    80% confidence
  • Wall Street analysts recommend caution with consensus Hold rating for Joby Aviation

    80% confidence
  • For Joby fiscal 2026, loss projected to narrow 11.8% to -$0.75 per share

    80% confidence
  • For Joby, full fiscal year losses seen growing 7.6% annually to -$0.85 per share

    80% confidence
  • Archer Aviation has consensus Moderate Buy rating overall

    80% confidence
  • For Archer current year, losses projected to decline 27.5% YOY to -$1.03 per share

    80% confidence
Ce que nous savons · l'intelligence derrière cette page
En direct du substrat
Ce que nous observons
Q4 2026 Biotech Catalyst Cluster: Late-Stage Data and PDUFA Dates Converge
Early-to-mid November 2026 is a dense run of clinical readouts and Q3 earnings at AHA, AASLD, ACR and ASH. Mid-cap biotechs (Vir, Mineralys, Arrowhead, Oryzon, Novartis, J&J) are reporting data that feeds into regulatory decisions. The next ones are the ivonescimab BLA (Nov 14) and the lorundrostat PDUFA (Dec 22), followed by ECLIPSE 2/3 and Maritime-1 readouts in Q1 2027. The list also includes an unrelated delisting track (EGM Nov 19, application Jan 25, 2027), and the facts have no AI or fintech content.
Notre lecture des données ›
Signaux que nous suivons
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Tendances que nous surveillons ›
Là où les sources divergent
Un éditeur vérifie les conflits entre sources avant de les publier ici.
Nous signalons les conflits ouvertement ›
Vérifié récemment
✓ Vérifié avec la source d'origine
4,959
faits reliés à leur source, et nous signalons ceux qui ne tiennent pas.
101 entités suivies4,959 faits vérifiés avec la source5,585 documents sources archivés
Interrogez ces données → isubstrate.com

Données de travail, pas l’article final. Voici ce que notre IA a lu et extrait des documents sources jusqu’ici. Notre méthode

2 Top Flying Car Stocks That Cathie Wood Can’t Get Enough Of: Source | Via News | fr.via.news